$CMPX has received 4 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention on April 27, 2026. @jacobplieth (@jacobplieth) is the most active voice discussing the ticker, accounting for 4 of the 5 mentions, while @adamfeuerstein (Adam Feuerstein ✡️) contributed 1 mention. The biotech category dominates discussion of Compass Therapeutics Inc, reflecting the company's clinical development focus.

Initial discussion centered on clinical trial results reported on April 27, 2026, relating to the drug candidate tovecimig. @adamfeuerstein documented receiving unverified information claiming positive progression-free survival and overall survival data prior to official announcement, noting the information proved false upon release of actual results. @jacobplieth's commentary on the same date referenced patient crossover impacting overall survival outcomes. The most recent mention occurred on July 17, 2026, when @jacobplieth referenced $CMPX alongside other biotech tickers in a hashtag for ESMO26.